These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23904442)

  • 1. CXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesis.
    Kramer JM; Klimatcheva E; Rothstein TL
    J Leukoc Biol; 2013 Nov; 94(5):1079-89. PubMed ID: 23904442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokines Up-Regulated in Epithelial Cells Control Senescence-Associated T Cell Accumulation in Salivary Glands of Aged and Sjögren's Syndrome Model Mice.
    Kurosawa M; Shikama Y; Furukawa M; Arakaki R; Ishimaru N; Matsushita K
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction.
    Sharma A; Kiripolsky J; Klimatcheva E; Howell A; Fereidouni F; Levenson R; Rothstein TL; Kramer JM
    Clin Immunol; 2016 Mar; 164():85-94. PubMed ID: 26826598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished CXCR5 expression in peripheral blood of patients with Sjögren's syndrome may relate to both genotype and salivary gland homing.
    Aqrawi LA; Ivanchenko M; Björk A; Ramírez Sepúlveda JI; Imgenberg-Kreuz J; Kvarnström M; Haselmayer P; Jensen JL; Nordmark G; Chemin K; Skarstein K; Wahren-Herlenius M
    Clin Exp Immunol; 2018 Jun; 192(3):259-270. PubMed ID: 29453859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome.
    Chatzis L; Goules AV; Stergiou IE; Voulgarelis M; Tzioufas AG; Kapsogeorgou EK
    Front Immunol; 2021; 12():705079. PubMed ID: 34484201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases.
    Hernández-Molina G; Michel-Peregrina M; Hernández-Ramírez DF; Sánchez-Guerrero J; Llorente L
    Rheumatology (Oxford); 2011 Jul; 50(7):1288-92. PubMed ID: 21330342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome.
    Zhao J; Kubo S; Nakayamada S; Shimajiri S; Zhang X; Yamaoka K; Tanaka Y
    Mod Rheumatol; 2016 Sep; 26(5):716-24. PubMed ID: 26706891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome.
    Amft N; Curnow SJ; Scheel-Toellner D; Devadas A; Oates J; Crocker J; Hamburger J; Ainsworth J; Mathews J; Salmon M; Bowman SJ; Buckley CD
    Arthritis Rheum; 2001 Nov; 44(11):2633-41. PubMed ID: 11710719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjögren's syndrome.
    Salomonsson S; Larsson P; Tengnér P; Mellquist E; Hjelmström P; Wahren-Herlenius M
    Scand J Immunol; 2002 Apr; 55(4):336-42. PubMed ID: 11967114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR7 Signaling Drives the Development of Sjögren's Syndrome.
    Wang Y; Roussel-Queval A; Chasson L; Hanna Kazazian N; Marcadet L; Nezos A; Sieweke MH; Mavragani C; Alexopoulou L
    Front Immunol; 2021; 12():676010. PubMed ID: 34108972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive significance of CCL21 and CXCL13 levels in the minor salivary glands of patients with Sjögren's syndrome.
    Lee KE; Kang JH; Yim YR; Kim JE; Lee JW; Wen L; Park DJ; Kim TJ; Park YW; Yoon KC; Lee JS; Lee SS
    Clin Exp Rheumatol; 2017; 35(2):234-240. PubMed ID: 27782867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated CXCL13 in primary Sjögren's syndrome and its correlation with disease activity: a systematic review and meta-analysis.
    Zhu T; Pan Z; Zhang N
    Clin Rheumatol; 2022 Sep; 41(9):2791-2802. PubMed ID: 35616754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CP-25 alleviates antigen-induced experimental Sjögren's syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration.
    Wu H; Chen X; Gu F; Zhang P; Xu S; Liu Q; Zhang Q; Wang X; Wang C; Körner H; Wei W
    Lab Invest; 2021 Aug; 101(8):1084-1097. PubMed ID: 32620868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice.
    Gatumu MK; Skarstein K; Papandile A; Browning JL; Fava RA; Bolstad AI
    Arthritis Res Ther; 2009; 11(1):R24. PubMed ID: 19222863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with 60 kD Ro peptide produces different stages of preclinical autoimmunity in a Sjögren's syndrome model among multiple strains of inbred mice.
    Kurien BT; Dsouza A; Igoe A; Lee YJ; Maier-Moore JS; Gordon T; Jackson M; Scofield RH
    Clin Exp Immunol; 2013 Jul; 173(1):67-75. PubMed ID: 23607771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome.
    Barone F; Bombardieri M; Manzo A; Blades MC; Morgan PR; Challacombe SJ; Valesini G; Pitzalis C
    Arthritis Rheum; 2005 Jun; 52(6):1773-84. PubMed ID: 15934082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alleviating effect of paeoniflorin-6'-O-benzene sulfonate in antigen-induced experimental Sjögren's syndrome by modulating B lymphocyte migration via CXCR5-GRK2-ERK/p38 signaling pathway.
    Chen X; Zhang P; Liu Q; Zhang Q; Gu F; Xu S; Körner H; Wu H; Wei W
    Int Immunopharmacol; 2020 Mar; 80():106199. PubMed ID: 31955068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL13 as biomarker for histological involvement in Sjögren's syndrome.
    Colafrancesco S; Priori R; Smith CG; Minniti A; Iannizzotto V; Pipi E; Lucchesi D; Pontarini E; Nayar S; Campos J; Arienzo F; Fusconi M; Cerbelli B; Giordano C; Valesini G; Bombardieri M; Fisher BA; Barone F
    Rheumatology (Oxford); 2020 Jan; 59(1):165-170. PubMed ID: 31274159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren's syndrome and in mice.
    Yin H; Cabrera-Perez J; Lai Z; Michael D; Weller M; Swaim WD; Liu X; Catalán MA; Rocha EM; Ismail N; Afione S; Rana NA; Di Pasquale G; Alevizos I; Ambudkar I; Illei GG; Chiorini JA
    Arthritis Rheum; 2013 Dec; 65(12):3228-38. PubMed ID: 23982860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.
    Fava RA; Kennedy SM; Wood SG; Bolstad AI; Bienkowska J; Papandile A; Kelly JA; Mavragani CP; Gatumu M; Skarstein K; Browning JL
    Arthritis Res Ther; 2011; 13(6):R182. PubMed ID: 22044682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.